Abstract: A method of treating an HIV infected subject includes administering the subject an enriched CCR5 and/or CXCR4 gene edited CD4+ T cell population characterized by intermediate cells surface co-expression of CD45A and CD45O (RAintROint).

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: A method of generating an enriched population of T cells for use in adoptive immunotherapy applications includes isolating T-cells from a biological sample of a subject, and separating a population of CD4/CD8 T cells having a CD45RAintCD45ROint phenotype from the isolated T cells.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.

Abstract: Disclosed are methods of detecting and isolating CD4+ T cells latently infected with HIV as well as methods of screening for inhibitors of CD4+ T cells latently infected with HIV.

Abstract: Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed.

Abstract: Modulation of PD-1 activity in the presence or absence of an agent as measured by a gene expression profile of at least two genes is provided. Reagents, kits, methods and uses thereof for the modulation of immune function comprise the identification of modulators of PD-1 activity.

Abstract: Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: Reagents, kits, methods and uses thereof useful for the modulation of immune function, such as the identification of modulators of PD-1 activity, are described. Such reagents, kits, methods and uses thereof may be useful, for example, in the diagnosis, prognostication, prevention and/or treatment of immune-related diseases and/or conditions.

Abstract: Methods, uses, products and kits are described relating to monitoring, assessing and modulating immune function and more particularly memory T cell function. Methods of identifying agents for such modulation are also described, as well as uses of such agents for modulating immune function.

Abstract: A method of purifying a subpopulation of naive T cells that have recently emigrated from the thymus, comprising (a) contacting a biological sample susceptible of containing T cells with at least four different ligands, namely ligands directed to the markers CD3, CD4, CD45RA, and CD31; (b) sorting the cells so as to recover T cells having a phenotype comprising at least the following four markers CD3+, CD4+, CD45RA+ and CD31hi, whereby a subpopulation of naive T cells is purified.

Abstract: The present invention relates to a DNA construct for in vivo expression in an excision DNA circle created by DNA recombination machinery in T cells from a non-human mammal which comprises two recombination signal sequences (RSS) consensus sequences flanking a promoter, an enhancer and a reporter gene, wherein the excision DNA circle is diluted out after cellular division and the excision DNA circle is detected by expression of the reporter gene and the detection is indicative of thymic function activity of the mammal. The present invention also relates to a T cell transiently transfected with the DNA construct of the present invention, the cell expressing quantifiable levels of reporter gene for green fluorescent protein (GFP) for determining enhancing/decreasing thymic exportation, a mammal comprising the DNA construct of the present invention and methods thereof.